跳至主要内容
临床试验/NCT01065402
NCT01065402Unknown不适用

A Randomized, Two-Regimen, Crossover, Comparative Study to Evaluate the Efficacy and Safety of PPB-R-203-Based Meal Versus TK9-Based Meal in 20 Patients With Diabetes

Pharma Power Biotec Co., Ltd.2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2010年2月最近更新:
适应症

试验速览

阶段
不适用
入组人数
20
试验地点
2
主要终点
The daily blood glucose level will be monitored by the continuous glucose monitoring system (CGMS) device Medtronic MiniMed.

研究概览

简要总结

To evaluate the efficacy of PPB-R-203-Based Meal and TK9-Based Meal on blood glucose control in 20 patients with diabetes for 2 days.

详细描述

The MiniMed Medtronic CGMS (continuous glucose monitoring system), the first model approved by FDA, was used for subcutaneous glucose monitoring. The CGMS continually measures the glucose concentration of the interstitial fluid every 10 seconds and then stores an average glucose value for each 5 minutes period, for a total of up to 288 measurements each day.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Health Services Research
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diabetes mellitus patient.
  • Aged between 20 to 65 years old.
  • Informed consent form signed.

排除标准

  • A recent history of drug or alcohol abuse.
  • Sensitivity to analogous product.
  • Serious cardiovascular disorders.
  • Participation in another clinical investigation study.
  • Ongoing influenza, autoimmune disease and other metabolic diseases.
  • Pregnant or lactating women.
  • Individuals are judged by the investigators or co-investigator to be undesirable as subjects.

结局指标

主要结局

The daily blood glucose level will be monitored by the continuous glucose monitoring system (CGMS) device Medtronic MiniMed.

时间窗: 2 days

次要结局

未报告次要终点

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验